Patients who use medicinal cannabis to be assessed for changes in quality-of-life outcomes

1w
3m read
Summary

The study is being touted as one of the largest in the world to examine the quality of life (QoL) outcomes for patients who use medicinal cannabis, the university announced this week. Funded by Australian medicinal cannabis manufacturer, Little Green Pharma, the company will provide technical advice on its products and their administration, but data collection and analysis will be carried out independently. A wide-ranging longitudinal study involving thousands of medical cannabis patients in Australia is trying to get a fix on many related issues, ranging from anxiety to health costs. The study is open to patients with a broad range of chronic conditions and diseases, including chronic pain, cancer pain, neuropathic pain, insomnia, anxiety, multiple sclerosis and epilepsy, the university reports. University of Sydney researchers have launched The QUality of life Evaluation STudy (The QUEST Initiative), which is set to close in March 2022.

Article Preview

A wide-ranging longitudinal study involving thousands of medical cannabis patients in Australia is trying to get a fix on many related issues, ranging from anxiety to health costs.

University of Sydney researchers have launched The QUality of life Evaluation STudy (The QUEST Initiative), which is set to close in March 2022. The study is being touted as one of the largest in the world to examine the quality of life (QoL) outcomes for patients who use medicinal cannabis, the university announced this week.

By this...

Read the full article @ The Growth Op